Roy D. Baynes's Insider Trades & SAST Disclosures
Roy D. Baynes's most recent trade in Nurix Therapeutics Inc was a trade of 25,000 Director Stock Option (right to buy) done . Disclosure was reported to the exchange on May 19, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Roy D. Baynes.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Nurix Therapeutics Inc | Roy D. Baynes | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 May 2025 | 25,000 | 25,000 | - | - | Director Stock Option (right to buy) | |
| Travere Therapeutics Inc | Roy D. Baynes | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2025 | 19,500 | 19,500 | - | - | Stock option (right to buy) | |
| Travere Therapeutics Inc | Roy D. Baynes | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2025 | 6,500 | 37,500 (0%) | 0% | 0 | Common Stock | |
| Natera Inc | Roy D. Baynes | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Apr 2025 | 116 | 16,015 (0%) | 0% | - | Common Stock | |
| Nurix Therapeutics Inc | Roy D. Baynes | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Mar 2025 | 50,000 | 50,000 | - | - | Director Stock Option (right to buy) | |
| Travere Therapeutics Inc | Roy D. Baynes | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 17.44 per share. | 06 Feb 2025 | 10,000 | 41,000 (0%) | 0% | 17.4 | 174,400 | Common Stock |
| Travere Therapeutics Inc | Roy D. Baynes | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Feb 2025 | 10,000 | 0 | - | - | Stock option (right to buy) | |
| Travere Therapeutics Inc | Roy D. Baynes | Director | Sale of securities on an exchange or to another person at price $ 22.00 per share. | 06 Feb 2025 | 10,000 | 31,000 (0%) | 0% | 22 | 220,000 | Common Stock |
| Natera Inc | Roy D. Baynes | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 92 | 15,899 (0%) | 0% | - | Common Stock | |
| Travere Therapeutics Inc | Roy D. Baynes | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Jan 2025 | 16,000 | 0 | - | - | Stock option (right to buy) | |
| Travere Therapeutics Inc | Roy D. Baynes | Director | Sale of securities on an exchange or to another person at price $ 20.00 per share. | 23 Jan 2025 | 16,000 | 31,000 (0%) | 0% | 20 | 320,000 | Common Stock |
| Travere Therapeutics Inc | Roy D. Baynes | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 17.50 per share. | 23 Jan 2025 | 16,000 | 47,000 (0%) | 0% | 17.5 | 280,000 | Common Stock |
| Natera Inc | Roy D. Baynes | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 22.83 per share. | 15 Nov 2024 | 22,000 | 37,807 (0%) | 0% | 22.8 | 502,260 | Common Stock |
| Natera Inc | Roy D. Baynes | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Nov 2024 | 22,000 | 0 | - | - | Stock Option (right to buy) | |
| Natera Inc | Roy D. Baynes | Director | Sale of securities on an exchange or to another person at price $ 145.21 per share. | 15 Nov 2024 | 16,404 | 31,133 (0%) | 0% | 145.2 | 2,381,997 | Common Stock |
| Natera Inc | Roy D. Baynes | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 24.42 per share. | 15 Nov 2024 | 15,230 | 53,037 (0%) | 0% | 24.4 | 371,917 | Common Stock |
| Natera Inc | Roy D. Baynes | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Nov 2024 | 15,230 | 0 | - | - | Stock Option (right to buy) | |
| Natera Inc | Roy D. Baynes | Director | Sale of securities on an exchange or to another person at price $ 147.31 per share. | 15 Nov 2024 | 9,467 | 19,896 (0%) | 0% | 147.3 | 1,394,620 | Common Stock |
| Natera Inc | Roy D. Baynes | Director | Sale of securities on an exchange or to another person at price $ 144.26 per share. | 15 Nov 2024 | 5,500 | 47,537 (0%) | 0% | 144.3 | 793,419 | Common Stock |
| Natera Inc | Roy D. Baynes | Director | Sale of securities on an exchange or to another person at price $ 148.74 per share. | 15 Nov 2024 | 2,106 | 17,790 (0%) | 0% | 148.7 | 313,250 | Common Stock |
| Natera Inc | Roy D. Baynes | Director | Sale of securities on an exchange or to another person at price $ 149.98 per share. | 15 Nov 2024 | 1,983 | 15,807 (0%) | 0% | 150.0 | 297,408 | Common Stock |
| Natera Inc | Roy D. Baynes | Director | Sale of securities on an exchange or to another person at price $ 146.25 per share. | 15 Nov 2024 | 1,770 | 29,363 (0%) | 0% | 146.3 | 258,871 | Common Stock |
| Natera Inc | Roy D. Baynes | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Oct 2024 | 124 | 15,807 (0%) | 0% | - | Common Stock | |
| Natera Inc | Roy D. Baynes | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jul 2024 | 143 | 15,683 (0%) | 0% | - | Common Stock | |
| Natera Inc | Roy D. Baynes | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jun 2024 | 2,964 | 15,540 (0%) | 0% | - | Common Stock | |
| Travere Therapeutics Inc | Roy D. Baynes | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 May 2024 | 19,500 | 19,500 | - | - | Stock option (right to buy) | |
| Travere Therapeutics Inc | Roy D. Baynes | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 May 2024 | 6,500 | 31,000 (0%) | 0% | 0 | Common Stock | |
| Natera Inc | Roy D. Baynes | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Apr 2024 | 169 | 12,576 (0%) | 0% | - | Common Stock | |
| Natera Inc | D. Roy Baynes | Director | Grant, award, or other acquisition of securities at price $ 63.79 per share. | 26 Jan 2024 | 215 | 12,407 (0%) | 0% | 63.8 | 13,715 | Common Stock |
| Natera Inc | Roy D. Baynes | Director | Grant, award, or other acquisition of securities at price $ 48.48 per share. | 28 Jul 2023 | 264 | 11,870 (0%) | 0% | 48.5 | 12,799 | Common Stock |
| Natera Inc | Roy D. Baynes | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2023 | 4,255 | 4,255 | - | - | Stock Option (right to buy) | |
| Natera Inc | Roy D. Baynes | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2023 | 2,750 | 11,606 (0%) | 0% | - | Common Stock | |
| Travere Therapeutics Inc | Roy D. Baynes | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 May 2023 | 13,500 | 13,500 | - | - | Stock option (right to buy) | |
| Travere Therapeutics Inc | Roy D. Baynes | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 May 2023 | 4,500 | 24,500 (0%) | 0% | 0 | Common Stock | |
| Natera Inc | Roy D. Baynes | Director | Grant, award, or other acquisition of securities at price $ 54.73 per share. | 14 Apr 2023 | 228 | 5,322 (0%) | 0% | 54.7 | 12,478 | Common Stock |
| Natera Inc | Roy D. Baynes | Director | Grant, award, or other acquisition of securities at price $ 40.01 per share. | 13 Jan 2023 | 312 | 5,094 (0%) | 0% | 40.0 | 12,483 | Common Stock |
| Natera Inc | Roy D. Baynes | Director | Grant, award, or other acquisition of securities at price $ 45.42 per share. | 14 Oct 2022 | 275 | 4,782 (0%) | 0% | 45.4 | 12,491 | Common Stock |
| Natera Inc | Roy D. Baynes | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jul 2022 | 344 | 344 | - | - | Restricted Stock Unit | |
| Atara Biotherapeutics Inc | Roy D. Baynes | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jun 2022 | 31,500 | 31,500 | - | - | Non-Qualified Stock Option (Right to Buy) | |
| Atara Biotherapeutics Inc | Roy D. Baynes | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jun 2022 | 20,500 | 43,500 (0%) | 0% | 0 | Common Stock | |
| Natera Inc | Roy D. Baynes | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 May 2022 | 7,068 | 7,068 | - | - | Stock Option (right to buy) | |
| Natera Inc | Roy D. Baynes | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 May 2022 | 3,534 | 3,534 | - | - | Restricted Stock Unit | |
| Travere Therapeutics Inc | Roy D. Baynes | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 May 2022 | 9,000 | 9,000 | - | - | Stock option (right to buy) | |
| Travere Therapeutics Inc | Roy D. Baynes | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 May 2022 | 3,000 | 20,000 (0%) | 0% | 0 | Common Stock | |
| Atara Biotherapeutics Inc | Roy D. Baynes | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2021 | 17,500 | 17,500 | - | - | Non-Qualified Stock Option (Right to Buy) | |
| Atara Biotherapeutics Inc | Roy D. Baynes | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2021 | 11,000 | 23,000 (0%) | 0% | 0 | Common Stock | |
| Natera Inc | Roy D. Baynes | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 May 2021 | 2,856 | 0 | - | - | Restricted Stock Unit | |
| Natera Inc | Roy D. Baynes | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 May 2021 | 2,856 | 2,856 (0%) | 0% | - | Common Stock | |
| Natera Inc | Roy D. Baynes | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 May 2021 | 2,614 | 2,614 | - | - | Stock Option (right to buy) | |
| Natera Inc | Roy D. Baynes | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 May 2021 | 1,307 | 1,307 | - | - | Restricted Stock Unit | |
| Travere Therapeutics Inc | Roy D. Baynes | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 May 2021 | 9,000 | 9,000 | - | - | Stock option (right to buy) | |
| Travere Therapeutics Inc | Roy D. Baynes | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 May 2021 | 3,000 | 17,000 (0%) | 0% | 0 | Common Stock | |
| Natera Inc | Roy D. Baynes | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Aug 2020 | 1,300 | 15,230 | - | - | Stock Option (right to buy) | |
| Natera Inc | Roy D. Baynes | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 24.42 per share. | 07 Aug 2020 | 1,300 | 1,300 (0%) | 0% | 24.4 | 31,746 | Common Stock |
| Natera Inc | Roy D. Baynes | Director | Sale of securities on an exchange or to another person at price $ 53.47 per share. | 07 Aug 2020 | 1,300 | 0 (0%) | 0% | 53.5 | 69,513 | Common Stock |
| Atara Biotherapeutics Inc | Roy D. Baynes | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2020 | 24,500 | 24,500 | - | - | Non-Qualified Stock Option (Right to Buy) | |
| Atara Biotherapeutics Inc | Roy D. Baynes | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2020 | 8,000 | 12,000 (0%) | 0% | 0 | Common Stock | |
| Natera Inc | Roy D. Baynes | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2020 | 5,712 | 5,712 | - | - | Stock Option (right to buy) | |
| Natera Inc | Roy D. Baynes | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2020 | 2,856 | 2,856 | - | - | Restricted Stock Units |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges